[Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment].
The efficacy, tolerability and safety of simvastatin in the treatment of hyperlipemia in uremic patients undergoing hemodialysis were evaluated in 6 patients; a further 6 patients were treated with placebo and represented the control group. All patients treated completed the study. No clinical or laboratory side-effects were noted during the entire period of observation. Simvastatin caused a significant 26% reduction in total cholesterol, a 36% reduction in LDL cholesterol and a 28% reduction in triglycerides; HDL cholesterol and Apolipoprotein A increased by 19% and 12% respectively.
Fiorini
F
F
Servizio Dialisi, USL n. 2 Sanremese, Ospedale di Bussana, Imperia.
Patrone
E
E
Ardu
F
F
Castelluccio
A
A
D000368:Aged; D003402:Creatine Kinase / Q000097:blood; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007527:Isoenzymes; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008111:Liver Function Tests; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D019821:Simvastatin; D014511:Uremia / Q000097:blood / Q000150:complications / Q000628:therapy
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007527:Isoenzymes; D008055:Lipids; D008074:Lipoproteins; D008148:Lovastatin; D019821:Simvastatin; D003402:Creatine Kinase
Efficacia e sicurezza della simvastatina nella terapia dell'iperlipemia nei pazienti uremici in trattamento emodialitico.